- Home
- ARDT vs ADPT Comparison
ARDT vs ADPT Comparison
Compare ARDT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDT
- ADPT
- Stock Information
- Founded
- ARDT 2001
- ADPT 2009
- Country
- ARDT United States
- ADPT United States
- Employees
- ARDT N/A
- ADPT N/A
- Industry
- ARDT
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARDT
- ADPT Health Care
- Exchange
- ARDT NYSE
- ADPT Nasdaq
- Market Cap
- ARDT 2.1B
- ADPT 1.8B
- IPO Year
- ARDT 2024
- ADPT 2019
- Fundamental
- Price
- ARDT $11.12
- ADPT $10.47
- Analyst Decision
- ARDT Buy
- ADPT Strong Buy
- Analyst Count
- ARDT 13
- ADPT 7
- Target Price
- ARDT $20.43
- ADPT $10.57
- AVG Volume (30 Days)
- ARDT 408.4K
- ADPT 2.4M
- Earning Date
- ARDT 08-13-2025
- ADPT 08-05-2025
- Dividend Yield
- ARDT N/A
- ADPT N/A
- EPS Growth
- ARDT 935.52
- ADPT N/A
- EPS
- ARDT 1.64
- ADPT N/A
- Revenue
- ARDT $6,024,260,000.00
- ADPT $189,527,000.00
- Revenue This Year
- ARDT $8.25
- ADPT $24.39
- Revenue Next Year
- ARDT $5.56
- ADPT $20.44
- P/E Ratio
- ARDT $6.81
- ADPT N/A
- Revenue Growth
- ARDT 8.91
- ADPT 8.61
- 52 Week Low
- ARDT $11.14
- ADPT $3.85
- 52 Week High
- ARDT $20.72
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- ARDT N/A
- ADPT 45.50
- Support Level
- ARDT N/A
- ADPT $10.45
- Resistance Level
- ARDT N/A
- ADPT $12.36
- Average True Range (ATR)
- ARDT 0.00
- ADPT 0.49
- MACD
- ARDT 0.00
- ADPT -0.21
- Stochastic Oscillator
- ARDT 0.00
- ADPT 11.55
About ARDT ARDENT HEALTH PARTNERS INC
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in services and technologies, Ardent is passionate about making healthcare easier to access.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).